GDTC CytoMed Therapeutics Limited
Healthcare$1.15+1.77%ClosedMarket Cap: $13.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.04
P/S
31.38
EV/EBITDA
-2.75
DCF Value
$0.05
FCF Yield
-39.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
-64.0%
Operating Margin
-1075.1%
Net Margin
-1062.1%
ROE
-75.3%
ROA
-56.7%
ROIC
-62.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 null | $167.9K | -330.9% | $-2.4M | $-1.7M | $— | — |
| FY null | $319.2K | -277.7% | $-4.5M | $-3.9M | $— | — |
| Q2 null | $105.7K | 93.1% | $-510.6K | $-882.3K | $— | — |
| Q1 null | $100.0K | 93.1% | $-483.2K | $-835.0K | $— | — |
| Q4 null | $52.4K | 174.9% | $-1.2M | $-1.1M | $— | — |
| FY null | $52.0K | 100.7% | $-2.6M | $-1.9M | $— | — |
| Q3 null | $108.6K | 89.7% | $-397.8K | $-555.7K | $— | — |
| Q2 null | $82.7K | 99.0% | $-1.4M | $-808.0K | $— | — |
| Q1 null | $83.1K | 99.0% | $-393.3K | $-403.5K | $— | — |
| Q4 null | $84.7K | 98.9% | $-331.0K | $-748.2K | $— | — |
| FY null | $290.6K | 131.4% | $-3.2M | $-3.1M | $— | — |
| Q3 2023 | $81.7K | 98.9% | $-663.2K | $-722.3K | $-0.06 | — |